Syneos Health announced a strategic partnership with Fosun Pharma USA Inc. As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One team for the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer (ES-SCLC), in the US. The therapy is the first innovative monoclonal antibody developed by Shanghai Henlius Biotech Inc. and Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the US upon regulatory approval. Serplulimab has the potential to be the world's first anti-PD-1 mAb for the first-line treatment of SCLC and is the first asset as part of the partnership with Syneos Health.

Over time, the partnership between the two companies is expected to expand further, continuing to leverage a product development team of experts and full commercial infrastructure within Syneos One to support Fosun Pharma USA's growth. Specifically, for Serplulimab, Syneos Health will provide Medical Affairs, Market Access, Marketing, Sales, and Operations capabilities, as well as staffing, to help Fosun bring new products to market and fill important unmet needs for patients. Syneos One solutions are unique in the market and can reduce program risk and optimize product development timelines, while maximizing return on investment.

Specifically, Syneos One covers the full clinical development, medical affairs and commercialization continuum. These solutions provide small to mid-sized customers with an economic alternative to divesting, out-licensing, or co-promoting assets, and offers large biopharmaceutical customers further opportunity to reduce their fixed-cost infrastructure and can be an alternative approach to developing and promoting non-core and established assets.